Product Images Gabapentin

This is a formula for estimating the creatinine clearance in patients, which is a measure of kidney function. It involves multiplying the patient's age in years by their weight in kilograms and multiplying by a correction factor of 0.85 for female patients, then multiplying by the serum creatinine level in mg/dL.*

This text appears to show a comparison of mean pain scores for two different periods: a dose titration period and a fixed dose period. The study involves two medications, assumed to be Piaceto and Gabapentin at a dosage of 3600 mg/day. The data is possibly presented using a numerical scale from 1 to 8 for each period.*

This document appears to be a table depicting a study or clinical trial assessing the effect of different doses of gabapentin on pain scores over an eight-week period. The table shows a 3-week dose titration period followed by a 4-week fixed dose period. The study includes three groups: a placebo group, a group taking 1800 mg/day of gabapentin, and a group taking 2400 mg/day of gabapentin. The pain scores are likely measured weekly, with baseline scores and scores at weeks 1 to 7 presented in the table.*

This text provides data on the proportion of responders in controlled studies for post-herpetic neuralgia (PHN) treatment. Study 1 had 29% responders and Study 2 had 1% responders. The different treatments evaluated were a placebo (PBO), GBP 300, GBP 1800, and GBP 2400.*

This is a product label for "SharsenTIN 600 MG" tablets. The product comes in a bottle containing 90 tablets. It should be stored at a temperature between 68 to 77 degrees Fahrenheit.*